{
    "id": 18873,
    "fullName": "PDPK1 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PDPK1 positive indicates the presence of the PDPK1 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5170,
        "geneSymbol": "PDPK1",
        "terms": [
            "PDPK1",
            "PDK1",
            "PDPK2",
            "PDPK2P",
            "PRO0461"
        ]
    },
    "variant": "positive",
    "createDate": "02/29/2016",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4799,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells treated with BX-320 demonstrated decreased cell growth in culture (PMID: 15772071).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3656,
                "therapyName": "BX-320",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4745,
                    "pubMedId": 15772071,
                    "title": "Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15772071"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4798,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BX-320 treatment in breast cancer cells resulted in decreased cell growth and apoptotic induction in culture (PMID: 15772071).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3656,
                "therapyName": "BX-320",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4745,
                    "pubMedId": 15772071,
                    "title": "Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15772071"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4814,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, prostate cancer cells were sensitive to BX-912, resulting in a moderate decrease of Pdpk1 activity and inhibition of cell growth in culture (PMID: 15772071).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3657,
                "therapyName": "BX-912",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4745,
                    "pubMedId": 15772071,
                    "title": "Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15772071"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4822,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells treated with GSK2334470 in both culture and xenograft models demonstrated decreased signaling of Pdpk1 and reduced cell proliferation (Cancer Res April 15, 2010 70; LB-116).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3662,
                "therapyName": "GSK2334470",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4753,
                    "pubMedId": null,
                    "title": "Abstract LB-116: GSK2334470: A potent and highly selective inhibitor of PDK1",
                    "url": "http://cancerres.aacrjournals.org/content/70/8_Supplement/LB-116.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4817,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combinational treatment of BX-912 and Velcade (bortezomib) produced an additive effect in multiple myeloma cells in culture, resulting in decreased cell viability (PMID: 25269480).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3658,
                "therapyName": "Bortezomib + BX-912",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4747,
                    "pubMedId": 25269480,
                    "title": "Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25269480"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4820,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, head and neck squamous cell carcinoma cells treated with OSU03012 (AR-12) in both culture and mouse models demonstrated reduced Akt levels, a marker for Pdpk1 activity, and tumor regression (PMID: 22491800).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 2408,
                "therapyName": "OSU03012",
                "synonyms": null
            },
            "indication": {
                "id": 5520,
                "name": "head and neck squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4749,
                    "pubMedId": 22491800,
                    "title": "Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22491800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4800,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BX-320 treatment resulted in decreased tumor growth when administered to mouse models injected with melanoma cells (PMID: 15772071).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3656,
                "therapyName": "BX-320",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4745,
                    "pubMedId": 15772071,
                    "title": "Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15772071"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4819,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combinatorial treatment of BX-912 and BAY11-7085 produced an additive effect in multiple myeloma cells in culture, resulting in decreased cell viability (PMID: 25269480).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3660,
                "therapyName": "BAY11-7085 + BX-912",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4747,
                    "pubMedId": 25269480,
                    "title": "Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25269480"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4816,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, multiple myeloma cells treated with BX-912 demonstrated cell cycle arrest and apoptotic activity (PMID: 25269480).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3657,
                "therapyName": "BX-912",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4747,
                    "pubMedId": 25269480,
                    "title": "Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25269480"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4818,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combinatorial treatment of BX-912 and Toposaur (etoposide) produced a synergistic effect in multiple myeloma cells in culture, resulting in decreased cell viability (PMID: 25269480).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3659,
                "therapyName": "BX-912 + Etoposide",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4747,
                    "pubMedId": 25269480,
                    "title": "Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25269480"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4823,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pancreatic cancer cells treated with PHT-427 in both culture and mouse models demonstrated inhibition of cell growth and a decrease in Pdpk1 phosphorylation (PMID: 20197390).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3148,
                "therapyName": "PHT-427",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4754,
                    "pubMedId": 20197390,
                    "title": "Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20197390"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4815,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, mantle cell lymphoma cells treated with BX-912 demonstrated a decrease in Pdpk1 expression and cell cycle arrest in culture (ASH Meeting, Nov 2013; Blood: 122(21)).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3657,
                "therapyName": "BX-912",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4746,
                    "pubMedId": null,
                    "title": "High Efficiency Of the PDPK1-Inhibitor, BX912, In MCL",
                    "url": "http://www.bloodjournal.org/content/122/21/3077?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4813,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, colon cancer cells were sensitive to BX-912, resulting in cell growth inhibition in culture (PMID: 15772071).",
            "molecularProfile": {
                "id": 19233,
                "profileName": "PDPK1 positive"
            },
            "therapy": {
                "id": 3657,
                "therapyName": "BX-912",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4745,
                    "pubMedId": 15772071,
                    "title": "Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15772071"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 19233,
            "profileName": "PDPK1 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}